Erectile Dysfunction Drugs Market Expected to Reach $5.1 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Erectile Dysfunction Drugs Market," The Erectile Dysfunction Drugs Market Size was valued at $2.69 billion in 2022, and is estimated to reach $5.1 billion by 2032, growing at a CAGR of 6.5% from 2023 to 2032. 

Erectile dysfunction (ED), also known as impotence, is a type of sexual dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual activity. Erectile dysfunction (ED) is a common condition that affects men of all ages, but it is more common in older men. The cause of erectile dysfunction (ED) can be physical, psychological, or a combination.

Physical causes include high blood pressure, diabetes, obesity, and hardening of the arteries. Psychological causes may include depression, stress, and anxiety. Treatment options for erectile dysfunction (ED) include medications, lifestyle changes, and surgery. Lifestyle changes such as quitting smoking, losing weight, and exercising may help improve erectile dysfunction (ED).   

The Erectile Dysfunction Drugs Market Trends are an increase in the incidence of erectile dysfunction and rise in the prevalence of psychological disorders such as depression, stress, and anxiety. For instance, according to the American Hospital Association (AHA), in 2020, it was estimated that about 21 million adults are diagnosed with behavioral or emotional disorders in the U.S.

In addition, a rise in awareness about the benefits associated with erectile dysfunction drugs in developing countries such as India and China further boosts the growth of the market.   However, side effects associated with erectile dysfunction drugs and the high cost of surgical treatments negatively impact the market growth during the forecast period.  

The Erectile Dysfunction Drugs Market Analysis is done on the basis of product, mode of administration, distribution channel, and region. On the basis of product, the market is classified into sildenafil, avanafil, tadalafil, udenafil, and others. On the basis of the mode of administration, the market is bifurcated into oral and injectable medications. On the basis of distribution channels, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy.

On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).  

On the basis of product, the sildenafil segment generated the highest revenue in 2022, owing to the increase in use of Viagra as the first-line medication for the treatment of erectile dysfunction, less expensive than other ED medications, and it is a highly effective drug with a success rate of more than 60%.  

However, the Tadalafil segment is expected to witness considerable market growth during the forecast period. Owing to the increased use of tadalafil as it offers quick onset of action and may last for more than 24 hours as compared with sildenafil.

On the basis of mode of administration, the oral segment generated maximum Erectile Dysfunction Drugs Market Share in 2022, owing to high demand for oral Viagra and Cialis, and the increase in patient preference towards oral medication as it is easy to administer, highly effective, and widely available in the market. 

However, the injectable medication segment is expected to witness considerable market growth during Erectile Dysfunction Drugs Market Forecast period.  Owing to the advantages offered by injectables as they offer quick onset of action within 10-25 minutes of administration and have a high success rate. Moreover, the availability of approved injectable drugs for erectile dysfunction and a surge in awareness about erectile dysfunction across the world.

On the basis of distribution channel, the hospital pharmacy segment generated the maximum Erectile Dysfunction Drugs Market Share in 2022, owing to availability of erectile dysfunction drugs of various strengths such as Viagra (25mg), Viagra (50mg), and Viagra (100mg) in hospital pharmacy, high purchasing power, and it provides specialized expertise in managing erectile dysfunction medications drives the growth of Erectile Dysfunction Drugs Market Size in forecast period. 

However, the retail pharmacy segment is expected to witness considerable market growth during the forecast period. Retail pharmacy are often the first point of contact for patients who are seeking treatment for erectile dysfunction, as retail pharmacy are stocked with various types of erectile dysfunction drugs such as Viagra, Cialis and Stendra 

On the basis of region, North America generated maximum revenue in 2022, owing to the strong presence of key players, robust healthcare infrastructure, and availability of approved erectile dysfunction drugs. Asia-Pacific witnessed the highest growth in 2022, and is expected to witness highest CAGR, owing to increase in patient population, surge in healthcare expenditure, and rise in awareness related to erectile dysfunction drugs. 

Asia-Pacific is expected to register a noteworthy CAGR throughout the forecast period, owing to the presence of large patient population, growth in awareness for erectile dysfunction drugs, and increase in public–private investments for unmet medical needs. 

Major players profiled in the Erectile Dysfunction Drugs industry are Pfizer Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sanofi, Inc, Sun Pharmaceutical Industries Ltd., Bayer AG, Vivus LLC., Adamed Pharma, Glenmark Pharmaceuticals Limited, and Cipla Ltd. 

Key findings of the study  

• By product, the sidenafil segment was the highest contributor to the Erectile Dysfunction Drugs Industry in 2022.  

• By mode of administration, the oral medication segment was the highest contributor to the market in 2022.  

• By distribution channel, hospital pharmacies dominated the market in 2022 and are expected to remain dominant during the forecast period.  

• By region, North America garnered the largest revenue share in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.